Ariad Pharmaceuticals Inc. (ARIA)
-NasdaqGS 19.57 
0.13(0.67%) 25 May 04:00 SGT|After Hours
:
19.50 0.07 (0.36%) 25 May 07:23 SGT
| Prev Close: | 19.44 |
|---|
| Open: | 19.42 |
|---|
| Bid: | 16.19 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 27.95 |
|---|
| Beta: | 1.32 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 19.09 - 19.75 |
|---|
| 52wk Range: | 15.13 - 25.40 |
|---|
| Volume: | 2,652,526 |
|---|
| Avg Vol (3m): | 3,129,540 |
|---|
| Market Cap: | 3.61B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.36 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 3 Humongous Health Care Stocks This Weekat Motley Fool(Sat, 25 May)
- Merck Stock Is a Good Investment (According to Merck)at Motley Fool(Sat, 25 May)
- MannKind's Run to Gloryat Motley Fool(Fri, 24 May)
- ARIAD to Present at the Deutsche Bank 38th Annual Healthcare ConferenceBusiness Wire(Thu, 23 May)
- Why one trader is selling puts in AriadoptionMONSTER(Thu, 23 May)
- Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Winnerat TheStreet(Thu, 23 May)
- Ariad's Cancer Drug Iclusig Extends The Gleevec Magicat Seeking Alpha(Thu, 23 May)
- ARIA July Options Begin Tradingat Forbes(Tue, 21 May)
- Ariad Pharmaceuticals Inc. Presents at UBS Global Healthcare Conference, May-20-2013 08:30 AMat Seeking Alpha(Tue, 21 May)
- Ariad reports $6.4M in 1Q sales of leukemia pillAP(Wed, 8 May)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 517.27 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.67 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.40 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | -1.16 |
|---|
Business Summary
ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing addition...
View More